Adding subcutaneous liraglutide to metformin reduces HbA1c more than adding oral sitagliptin in patients whose type 2 diabetes is poorly controlled with metformin alone

Evidence-Based Medicine

Volumn 15, Issue 4, 2010, Pages 115-116

  Fonseca, Vivian ^a   Desouza, Cyrus ^b   Khan, Amna N ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; SITAGLIPTIN;

ADD ON THERAPY; DRUG EFFICACY; GLYCEMIC CONTROL; HUMAN; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OUTCOME ASSESSMENT; SIDE EFFECT; STOMACH EMPTYING; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 77955252981     PISSN: 13565524     EISSN: 14736810     Source Type: Journal    
DOI: 10.1136/ebm1098     Document Type: Note

References (6)

1. Peters A. Incretin-based therapies: review of current clinical trial data. Am J Med 2010;123(3 Suppl):S28-37.
2. Nauck M, Marre M. Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgrad Med 2009;121:5-15.
3. Ahrén B, Foley JE, Ferrannini E, et al. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care 2010;33:730-2.
4. Arnolds S, Dellweg S, Clair J, et al. Further improvement in postprandial glucose control when adding exenatide (EXE) or sitagliptin (SITA) to combination therapy with insulin glargine (GLAR) and metformin (MET) - a proof-of-concept study. Diabetes Care 2010;(In Press).
5. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.
6. Ahrén B, Schweizer A, Dejager S, et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009;94:1236-43.